Search results for "kinases"

showing 10 items of 929 documents

Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis

2021

Objective Neddylation is a druggable and reversible ubiquitin-like post-translational modification upregulated in many diseases, including liver fibrosis, hepatocellular carcinoma, and more recently, non-alcoholic fatty liver disease (NAFLD). Herein, we propose to address the effects of neddylation inhibition and the underlying mechanisms in pre-clinical models of NAFLD. Methods Hepatic neddylation measured by immunohistochemical analysis and NEDD8 serum levels measured by ELISA assay were evaluated in NAFLD clinical and pre-clinical samples. The effects of neddylation inhibition by using a pharmacological small inhibitor, MLN4924, or molecular approaches were assessed in isolated mouse hep…

AdultMaleCoronavirus disease 2019 (COVID-19)AdolescentMLN4924[SDV.BC]Life Sciences [q-bio]/Cellular BiologyDiet High-Fat03 medical and health sciencesMiceYoung Adult0302 clinical medicineNon-alcoholic Fatty Liver DiseasePolitical scienceNAFLDmedia_common.cataloged_instanceAnimalsHumansEuropean unionNeddylationMolecular BiologyInternal medicineComputingMilieux_MISCELLANEOUS030304 developmental biologymedia_commonAged0303 health sciencesTOR Serine-Threonine KinasesFatty AcidsIntracellular Signaling Peptides and ProteinsCell BiologyMiddle AgedRC31-12453. Good healthMice Inbred C57BLRare tumorDisease Models AnimalDeptor; Fatty acid oxidation; MLN4924; mTOR; NAFLD; NeddylationDeptorFatty acid oxidationHepatocytesmTOR030211 gastroenterology & hepatologyChristian ministryOriginal ArticleHumanitiesSignal Transduction
researchProduct

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas.

1998

Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer characterized by a predisposition to develop multiple, bilateral papillary renal tumours. The pattern of inheritance of HPRC is consistent with autosomal dominant transmission with reduced penetrance. HPRC is histologically and genetically distinct from two other causes of inherited renal carcinoma, von Hippel-Lindau disease (VHL) and the chromosome translocation (3;8). Malignant papillary renal carcinomas are characterized by trisomy of chromosomes 7, 16 and 17, and in men, by loss of the Y chromosome. Inherited and sporadic clear cell renal carcinomas are characterized by inactivation of b…

AdultMaleGenetic LinkageUrologyMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaChromosomal translocationBiologyurologic and male genital diseasesY chromosomemedicine.disease_causeProto-Oncogene MasGermlineGermline mutationGeneticsmedicineMissense mutationHumansAmino Acid SequenceCarcinoma Renal CellGerm-Line MutationAgedKidneyMutationBinding SitesSequence Homology Amino Acidbusiness.industryReceptor Protein-Tyrosine KinasesMiddle AgedProtein-Tyrosine KinasesProto-Oncogene Proteins c-metmedicine.diseasePenetranceCarcinoma PapillaryKidney NeoplasmsPedigreemedicine.anatomical_structureProto-Oncogene Proteins c-metMutationCancer researchHereditary leiomyomatosis and renal cell carcinomaFemaleTrisomybusinessKidney cancerChromosomes Human Pair 7Nature genetics
researchProduct

Effect of Age and Lipoperoxidation in Rat and Human Adipose Tissue-Derived Stem Cells

2020

A wide range of clinical applications in regenerative medicine were opened decades ago with the discovery of adult stem cells. Highly promising adult stem cells are mesenchymal stem/stromal cells derived from adipose tissue (ADSCs), primarily because of their abundance and accessibility. These cells have multipotent properties and have been used extensively to carry out autologous transplants. However, the biology of these cells is not entirely understood. Among other factors, the regeneration capacity of these cells will depend on both their capacity of proliferation/differentiation and the robustness of the biochemical pathways that allow them to survive under adverse conditions like thos…

AdultMaleHomeobox protein NANOGAgingTime FactorsStromal cellArticle SubjectApoptosisBiologyRegenerative MedicineBiochemistryRegenerative medicineCell therapyAMP-Activated Protein Kinase KinasesPeptide Elongation Factor 2Sirtuin 1SOX2AnimalsHumansRats WistarLipoperoxidation.Cell ProliferationQH573-671SOXB1 Transcription FactorsStem CellsMesenchymal stem cellAge FactorsCell DifferentiationMesenchymal Stem CellsNanog Homeobox ProteinCell BiologyGeneral MedicineMiddle AgedRatsCell biologyOxidative StressAdipose TissueageFemaleLipid PeroxidationStem cellCytologyProtein KinasesResearch ArticleHeLa CellsAdult stem cell
researchProduct

Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.

2015

The dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) gene, located on chromosome 21q22.13 within the Down syndrome critical region, has been implicated in syndromic intellectual disability associated with Down syndrome and autism. DYRK1A has a critical role in brain growth and development primarily by regulating cell proliferation, neurogenesis, neuronal plasticity and survival. Several patients have been reported with chromosome 21 aberrations such as partial monosomy, involving multiple genes including DYRK1A. In addition, seven other individuals have been described with chromosomal rearrangements, intragenic deletions or truncating mutations that disrupt specificall…

AdultMaleMicrocephalyMonosomyDown syndromeAdolescentChromosomes Human Pair 21BiologyProtein Serine-Threonine KinasesArticleIntellectual DisabilityIntellectual disabilityGeneticsmedicineHumansAutistic DisorderChildGenetics (clinical)Chromosomal DeletionGeneticsProtein-Tyrosine Kinasesmedicine.diseasePhenotypeChild PreschoolSpeech delayMutationMicrocephalyAutismFemalemedicine.symptomChromosome DeletionDown SyndromeChromosome 21European journal of human genetics : EJHG
researchProduct

Interrelationships between Muscle Structure, Muscle Strength, and Running Economy

2003

The present study was designed to investigate possible differences in running economy (RE) among elite middle-distance runners by examining muscle structure and maximal isometric force (MVC).Ten young male runners ran at six different running speeds. During the running bouts, respiratory gases, and blood lactate were measured. Muscle biopsies were obtained from the vastus lateralis muscle for analyzing fiber type distribution, muscle fiber area, myosin heavy chain (MHC) composition, activities of a number of metabolic enzymes (citrate synthase, lactate dehydrogenase, phosphofruktokinase, and 3-hydroxyacyl-CoA-dehydrogenase), and titin isoforms.Energy expenditure (EE) increased linearly up t…

AdultMaleMuscle Fibers SkeletalMuscle ProteinsPhysical Therapy Sports Therapy and RehabilitationAnatomyContractile proteinStatistics NonparametricRunningOxygen ConsumptionMyosinMuscle strengthRunning economyHumansConnectinElectrophoresis Polyacrylamide GelOrthopedics and Sports MedicineMuscle fibreEnergy MetabolismMuscle SkeletalPsychologyProtein KinasesMedicine & Science in Sports & Exercise
researchProduct

Variation in genomic landscape of clear cell renal cell carcinoma across Europe

2014

The incidence of renal cell carcinoma (RCC) is increasing worldwide, and its prevalence is particularly high in some parts of Central Europe. Here we undertake whole-genome and transcriptome sequencing of clear cell RCC (ccRCC), the most common form of the disease, in patients from four different European countries with contrasting disease incidence to explore the underlying genomic architecture of RCC. Our findings support previous reports on frequent aberrations in the epigenetic machinery and PI3K/mTOR signalling, and uncover novel pathways and genes affected by recurrent mutations and abnormal transcriptome patterns including focal adhesion, components of extracellular matrix (ECM) and …

AdultMaleOncogene Proteins FusionRNA SplicingGeneral Physics and AstronomyBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyCohort StudiesTranscriptomePhosphatidylinositol 3-KinasesMutation RatemedicineHumansEpigeneticsCarcinoma Renal CellAgedAged 80 and overGeneticsFocal AdhesionsMutationMultidisciplinaryGenome HumanGene Expression ProfilingGenetic VariationGenomicsSequence Analysis DNAGeneral ChemistryMiddle Agedmedicine.diseaseHuman genetics3. Good healthEuropeGene Expression Regulation NeoplasticGene expression profilingClear cell renal cell carcinomaMutationFemaleCarcinogenesisClear cellSignal TransductionNature Communications
researchProduct

Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

2009

Purpose Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, has shown clinical activity in mantle cell lymphoma (MCL). We evaluated two dose regimens of temsirolimus in comparison with investigator's choice single-agent therapy in relapsed or refractory disease. Patients and Methods In this multicenter, open-label, phase III study, 162 patients with relapsed or refractory MCL were randomly assigned (1:1:1) to receive one of two temsirolimus regimens: 175 mg weekly for 3 weeks followed by either 75 mg (175/75-mg) or 25 mg (175/25-mg) weekly, or investigator's choice therapy from prospectively approved options. The primary end point was progression-free survival (P…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyAntineoplastic AgentsKaplan-Meier EstimateLymphoma Mantle-CellDisease-Free SurvivalDrug Administration ScheduleRidaforolimuschemistry.chemical_compoundRefractoryRecurrenceInternal medicinemedicineHumansProspective StudiesProtein Kinase InhibitorsAgedNeoplasm StagingAged 80 and overSirolimusbusiness.industryLymphoma Non-HodgkinTOR Serine-Threonine KinasesMiddle Agedmedicine.diseaseTemsirolimusSurgeryFludarabineOncologychemistryDrug Resistance NeoplasmSirolimusRefractory Mantle Cell LymphomaFemaleRituximabMantle cell lymphomabusinessProtein Kinasesmedicine.drugJournal of Clinical Oncology
researchProduct

Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral b…

2001

We examined safety and efficacy of STI-571 in 24 bcr/abl-positive patients with CML post PBSCT. At start of STI-571 therapy, nine patients presented in blast crisis (BC) or in accelerated phase (AP), and 15 in chronic phase (CP). Patients were evaluated for hematologic, cytogenetic and molecular response, survival and toxicity. In general, STI-571 was well tolerated in this heavily pretreated group of patients with a non-hematologic and hematologic toxicity profile similar to that observed in a previous phase I trial at comparable doses. Five of nine patients with CML in transformation (AP, BC) were evaluable for hematologic response. Two of five patients had transient reductions in WBC and…

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFusion Proteins bcr-ablAntineoplastic AgentsPhiladelphia chromosomeTransplantation AutologousPiperazinesLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansEnzyme InhibitorsChemotherapyABLbusiness.industryHematopoietic Stem Cell Transplantationbreakpoint cluster regionHematologyMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseCombined Modality TherapyHematologic ResponseBlood Cell CountPyrimidinesTreatment OutcomeImatinib mesylateOncologyBenzamidesToxicityImmunologyImatinib MesylateFemaleComplicationbusinessLeukemia
researchProduct

Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer

2015

Abstract Tumor growth in the context of EGFR inhibitor resistance may remain EGFR-dependent and is mediated by mechanisms including compensatory ligand upregulation and de novo gene alterations. Sym004 is a two-antibody mixture targeting nonoverlapping EGFR epitopes. In preclinical models, Sym004 causes significant EGFR internalization and degradation, which translates into superior growth inhibition in the presence of ligands. In this phase I trial, we observed grade 3 skin toxicity and hypomagnesemia as mechanism-based dose-limiting events during dose escalation. In dose-expansion cohorts of 9 and 12 mg/kg of Sym004 weekly, patients with metastatic colorectal cancer and acquired EGFR inhi…

AdultMaleProto-Oncogene Proteins B-rafClass I Phosphatidylinositol 3-KinasesColorectal cancerCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Antineoplastic AgentsContext (language use)Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9]LigandsPhosphatidylinositol 3-Kinaseschemistry.chemical_compoundCell Line TumorHumansMedicinePanitumumabNeoplasm MetastasisAgedEGFR inhibitorsAged 80 and overDose-Response Relationship DrugCetuximabbusiness.industryGene AmplificationAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseErbB ReceptorsClinical trialGenes rasTreatment OutcomeOncologychemistryMutationImmunologyCancer researchFemaleGrowth inhibitionColorectal Neoplasmsbusinessmedicine.drug
researchProduct

Repeated muscle biopsies through a single skin incision do not elicit muscle signaling, but IL-6 mRNA and STAT3 phosphorylation increase in injured m…

2011

To determine if muscle biopsies can be repeated using a single small (5–6 mm) skin incision without inducing immediate MAPK activation or inflammation in the noninjured areas, the phosphorylation of ERK1/2, p38-MAPK, c-Jun NH2-terminal kinases (JNKs), IκBα, IKKα, and signal transducer and activator of transcription 3 (STAT3) was examined concurrent with IL-6 mRNA in six muscle biopsies obtained from the vastus lateralis of five men. Four biopsies were obtained through the same incision (5–6 mm) from the right leg (taken at 0, 30, 123, and 126 min) and another two each from new incisions performed in the left leg (at 31 and 120 min), while the subjects rested supine. The first three biopsie…

AdultMaleSTAT3 Transcription FactorMAPK/ERK pathwaymedicine.medical_specialtyPathologyTime FactorsPhysiologyBiopsyInflammationp38 Mitogen-Activated Protein KinasesQuadriceps MuscleMuscular DiseasesNF-KappaB Inhibitor alphaPhysiology (medical)Internal medicinemedicineHumansRNA MessengerPhosphorylationSTAT3Interleukin 6Mitogen-Activated Protein Kinase 1Analysis of VarianceWound HealingMitogen-Activated Protein Kinase 3Skin incisionbiologyInterleukin-6JNK Mitogen-Activated Protein KinasesIl 6 mrnaI-kappa B KinaseUp-RegulationEndocrinologybiology.proteinSTAT proteinPhosphorylationI-kappa B Proteinsmedicine.symptomSignal TransductionJournal of Applied Physiology
researchProduct